More Japanese legal action over hepatitis infections
This article was originally published in Scrip
The Japanese government is facing a new health-related legal onslaught following the filing in district courts across the country of legal actions seeking damages and compensation for hepatitis B infections allegedly due to the reuse of needles in state-run mass inoculation programmes.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.